The Technical Analyst
Terns Pharmaceuticals, [TERN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Terns Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.65% $4.56
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 294.81 mill |
| EPS: | -1.270 |
| P/E: | -3.59 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 64.65 mill |
| Avg Daily Volume: | 0.897 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.59 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.61x |
| Company: PE -3.59 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.113 (-75.59%) $-3.45 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.94 - 5.18 ( +/- 13.55%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Vivo Opportunity, Llc | Sell | 136 255 | Common Stock |
| 2024-04-02 | Vivo Opportunity, Llc | Sell | 76 346 | Common Stock |
| 2024-04-03 | Vivo Opportunity, Llc | Sell | 103 870 | Common Stock |
| 2024-04-01 | Vivo Opportunity, Llc | Sell | 39 411 | Common Stock |
| 2024-04-02 | Vivo Opportunity, Llc | Sell | 22 084 | Common Stock |
| INSIDER POWER |
|---|
| 68.75 |
| Last 96 transactions |
| Buy: 25 215 859 | Sell: 2 318 163 |
Forecast:
16:00 - $4.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.56
Forecast 2: 16:00 - $4.56
Forecast 3: 16:00 - $4.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.56 (-0.65% ) |
| Volume | 0.828 mill |
| Avg. Vol. | 0.897 mill |
| % of Avg. Vol | 92.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TERN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $6.21 | N/A | Active |
|---|
TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Latest Press Releases
2024-04-10 16:05:00 - Press Release
Terns Pharmaceuticals Appoints Melita Sun Jung As Chief Business Officer
Foster city, calif., april 10, 2024 (globe newswire) -- terns pharmaceuticals, inc. (“terns” or the “company”) (nasdaq: tern), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of melita sun jung as chief business officer, effective april 22, 2024.
2024-03-14 16:05:00 - Press Release
Terns Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Corporate Updates
Interim data from initial dose escalation cohorts from phase 1 trial of tern-701 (allosteric bcr-abl) for treatment of cml expected in second half of 2024
2024-03-11 16:05:00 - Press Release
Terns Pharmaceuticals Announces Orphan Drug Designation Granted To Tern-701 For The Treatment Of Chronic Myeloid Leukemia
Foster city, calif., march 11, 2024 (globe newswire) -- terns pharmaceuticals, inc. (“terns” or the “company”) (nasdaq: tern), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the u.s. food and drug administration (fda) granted orphan drug designation for tern-701 for the treatment of chronic myeloid leukemia (cml). tern-701, the company's internally discovered allosteric bcr-abl tyrosine kinase inhibitor (tki), is in phase 1 clinical development with interim data from initial dose escalation cohorts expected in the second half of 2024.
2024-03-07 16:05:00 - Press Release
Terns Pharmaceuticals Reports Inducement Grant To New Employee Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif., march 07, 2024 (globe newswire) -- terns pharmaceuticals, inc. (“terns” or the “company”) (nasdaq: tern), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of march 1, 2024 an equity inducement award to a new employee under the terms of the 2022 employment inducement award plan, as amended (the “inducement plan”). the equity award was approved by the compensation committee of the company's board of directors in accordance with nasdaq listing rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with terns.
2024-02-27 16:05:00 - Press Release
Terns Pharmaceuticals To Participate In Upcoming March Investor Conferences
Foster city, calif., feb. 27, 2024 (globe newswire) -- terns pharmaceuticals, inc. (“terns” or the “company”) (nasdaq: tern), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in march.
Latest News
2024-03-28 15:02:00 - Market Watch
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could send the stock sharply higher.
2024-03-25 15:00:00 - InvestorPlace
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
2024-01-17 15:40:55 - CNBC
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.
2023-11-29 16:05:00 - GlobeNewsWire
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit. Details are as follows:
2023-11-09 08:05:00 - GlobeNewsWire
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in the following upcoming investor conferences in November.
2023-10-19 16:05:00 - GlobeNewsWire
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of management will be participating in the following upcoming investor conferences:
2023-10-09 09:19:04 - Seeking Alpha
Terns Pharmaceuticals: Business Model Does Not Impress
Terns Pharmaceuticals stock is down 15% in the past 10 months, despite bullish articles following a bearish prediction. The company initially planned to develop drugs for the Chinese market but switched to developing US drugs for US consumers. Terns' lead candidate TERN-501, a THR-β agonist, lacks convincing data and faces competition in the NASH market.
2023-07-28 18:02:38 - GuruFocus
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an overview of both the guru and the traded company, and analyze the potential implications of this move for value investors.
2023-07-20 13:11:48 - Seeking Alpha
Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth
TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits to Scemblix, some of which could become apparent as early as this year with some data from a partner's phase 1 trial. TERN's TERN-501 is set to produce data in Q3'23 from a phase 2a trial in nonalcoholic steatohepatitis (NASH).
2023-06-06 16:30:00 - GlobeNewsWire
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT.